Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1410-1419

  Muscolini, Michela ^a   Cianfrocca, Roberta ^a,b   Sajeva, Angela ^a   Mozzetti, Simona ^c   Ferrandina, Gabriella ^c   Costanzo, Antonio ^d   Tuosto, Loretta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HISTONE DEACETYLASE; PROTEIN BAX; PROTEIN P53; PROTEIN P73; TRICHOSTATIN A; CASPASE 3; COMPOUND DANSHEN DRIPPING PILLS; CYTOCHROME C; DNA BINDING PROTEIN; HYDROXAMIC ACID; LACTIC ACID DERIVATIVE; NUCLEAR PROTEIN; PHENOL DERIVATIVE; TP73 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; SECRETION; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; CYTOCHROMES C; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; HYDROXAMIC ACIDS; LACTATES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHENOLS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 49849092584     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0299     Document Type: Article

References (52)

1. Herrin VE, Thigpen JT. Chemotherapy for ovarian cancers: current concepts. Semin Surg Oncol 1999;17:181-8.
2. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
3. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59:3077-83.
4. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002;62:924-31.
5. Perego P, Gatti L, Righetti SC, et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer 2003;105:617-24.
6. Yang X, Zheng F, Xing H, et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 2004;130:423-8.
7. Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
8. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
9. Meijerink JP, Mensink EJ, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998;91:2991-7.
10. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
11. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
12. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997;94:2345-9.
13. Levrero M, De Laurenzi V, Costanzo A, et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000;113:1661-70.
14. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
15. Naka M, Ozaki T, Takada N, et al. Functional characterization of naturally occurring mutants (P405R and P425L) of p73α and p73β found in neuroblastoma and lung cancer. Oncogene 2001;20:3568-72.
16. Moll UM, Slade N. p63 and p73: roles in development and tumour formation. Mol Cancer Res 2004;2:371-86.
17. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2003;408:307-10.
18. Agarwal R, Kaye SB. Expression profiling and individualisation of treatment for ovarian cancer. Curr Opin Pharmacol 2006;6:345-9.
19. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987;47:414-8.
20. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23.
21. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J Exp Med 1998;188:1763-8.
22. Cianfrocca R, Muscolini M, Marzano V, et al. RelA/NF-κB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 2008;15:354-63.
23. Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat 2003;6:323-8.
24. 2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 2005;4:603-11.
25. Takai N, Kawamata N, Gui D, et al. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004;101:2760-70.
26. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol Oncol 2006;101:108-13.
27. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
28. Bratasz A, Weir NM, Parinandi NL, et al. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci US A 2006;103:3914-9.
29. Daikoku T, Tranguch S, Chakrabarty A, et al. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-δ signaling in epithelial ovarian cancer. Cancer Res 2007;67:5285-92.
30. Bernassola F, Salomoni P, Oberst A, et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 2004;199:1545-57.
31. Ito A, Kawaguchi Y, Lai CH, et al. MDM2-1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002;21:6236-45.
32. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 2002;9:175-86.
33. Luo J, Li M, Tang Y, et al. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci US A 2004;101:2259-64.
34. Sykes SM, Mellert HS, Holbert MA, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006;24:841-51.
35. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000;82:436-40.
36. Villedieu M, Louis MH, Dutoit S, et al. Absence of Bcl-xL downregulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007;105:31-44.
37. Williams J, Lucas PC, Griffith KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005;96:287-95.
38. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
39. Tsuruta Y, Mandai M, Konishi I, et al. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur J Cancer 2001;37:531-41.
40. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support a latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002;99:95-100.
41. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
42. De Laurenzi VD, Catani MV, Terrinoni A, et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ. Cell Death Differ 1999;6:389-90.
43. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998;58:5061-5.
44. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-9.
45. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
46. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:303-5.
47. Ono Y, Nonomura N, Harada Y, et al. Loss of p73 induction in a cisplatin-resistant bladder cancer cell line. Mol Urol 2001;5:25-30.
48. Concin N, Becker K, Slade N, et al. Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004;64:2449-60.
49. Pediconi N, Ianari A, Costanzo A, et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 2003;5:552-8.
50. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-11.
51. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000;408:377-81.
52. Cosma MP. Ordered recruitment: gene-specific mechanism of transcription activation. Mol Cell 2002;10:227-36.